Website: genewiz.com   |   LinkedIn: linkedin.com/company/genewiz

Genomics That Moves Science Forward

How GENEWIZ became the genomics partner of choice for researchers around the world

At a glance

  • Company: GENEWIZ from Azenta Life Sciences (genewiz.com)
  • Headquarters: South Plainfield, New Jersey, with labs across North America, Europe and Asia (European HQ: Leipzig, Germany)
  • Parent: Azenta, Inc. (Nasdaq: AZTA), Burlington, Massachusetts
  • Focus: Sanger sequencing, next-generation sequencing, gene synthesis, molecular biology, bioinformatics, and GLP and clinical genomic services
  • Working with PSG on: From incubator to exit – led commercial efforts

A global leader in genomics services

GENEWIZ’s mission is to advance the life sciences by making research more productive and cost-efficient through scalable services. Thousands of researchers at academic, pharmaceutical, biotech, agricultural and government institutions rely on GENEWIZ for superior data quality backed by hands-on technical support.

From sequence to discovery

  • Sanger sequencing: the fast, dependable workhorse of molecular biology labs
  • Next-generation sequencing: RNA-seq, single-cell, exome, Illumina sequencing, proteomics and high-throughput gene expression screening
  • DNA and RNA synthesis: gene synthesis, oligo synthesis and plasmid DNA preparation
  • Bioinformatics: analysis that turns data into answers
  • Regulated services: GLP-compliant and CLIA/CAP-accredited preclinical and clinical genomics

Investing in the future of gene synthesis

GENEWIZ continues to raise the bar. Gene Synthesis 2.0 simplifies how researchers design and order genes, shortening the path from sequence to experiment. In October 2026, Azenta announced strategic investments in the next generation of GENEWIZ gene synthesis, including the acquisition of SynPlexity and an exclusive licensing agreement with Elegen.